Lexicon Pharmaceuticals, Inc. (LXRX) stock
Close on Nov 13, 2026Market cap $796.47MP/E –Yield –
Lexicon Pharmaceuticals, Inc. saw revenue fall 45.6% to $38.54M over the twelve months to Sep 30, 2026. Free cash flow was -$67.85M. At the latest close the market valued the company at $796.47M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $796.47M
- P/E ratio
- –
- Price to sales
- 20.67
- Price to book
- 4.86
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $38.54M
- Net income
- -$62.35M
- EPS, diluted
- -$0.14
- Free cash flow
- -$67.85M
- Book value per share
- $0.37
- Diluted shares
- 445M
Trading
- Next earnings
- Mar 4, 2027 (estimated, before the open)
- Previous close
- $1.82
- Open
- $1.83
- Day's range
- $1.72 – $1.83
- Volume
- 1,893,364
- Average volume (20 days)
- 2,173,803
- Index membership
- Russell 2000 (since Jun 2026), Russell 3000
- Beta (5 years)
- 1.76
- 52-week range
- $1.10 – $2.68
- RSI (14 days)
- 58.2
- Volatility (1 year)
- 72.1%
- Relative volume
- 0.71×
- WACC
- 13.4%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2012, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | LXRX | S&P 500 | Difference | LXRX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +11.2% | -3.0% | +14.2 pts | ||
| 3 months | -23.5% | -2.8% | −20.7 pts | ||
| Year to date | +55.7% | +11.5% | +44.2 pts | ||
| 1 year | +24.3% | +13.5% | +10.8 pts | ||
| 3 years | +67.3% | +77.7% | −10.4 pts | +18.7% | +21.1% |
| 5 years | -64.9% | +72.6% | −137.5 pts | -18.9% | +11.5% |
| 10 years | -89.1% | +308.2% | −397.3 pts | -19.9% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Lexicon Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Update
- Results
- Update
About Lexicon Pharmaceuticals
Pharmaceutical Preparations
The company is a biopharmaceutical business focused on discovering, developing, and commercializing pharmaceutical therapies. Its primary commercial product is INPEFA (sotagliflozin), an oral medication prescribed to reduce cardiovascular risks, including heart failure hospitalizations and cardiac death in qualifying adults. The company's clinical pipeline includes sotagliflozin for hypertrophic cardiomyopathy and type 1 diabetes, pilavapadin for diabetic peripheral neuropathic pain, and LX9851 for obesity and related cardiometabolic conditions. It supplies its commercial treatments primarily to major and regional pharmaceutical wholesalers, which distribute the medications to hospitals, retail pharmacies, government institutions, and healthcare providers.
Company profile, executives and historyLexicon Pharmaceuticals stock: common questions
What is Lexicon Pharmaceuticals's stock price?
LXRX closed at $1.79 on Nov 13, 2026, down 1.65% on the day. Over the past 52 weeks it traded between $1.10 and $2.68.
What is Lexicon Pharmaceuticals's market cap?
Lexicon Pharmaceuticals was worth $796.47M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is LXRX's P/E ratio?
Lexicon Pharmaceuticals lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.14), so it has no meaningful P/E ratio.
How much revenue does Lexicon Pharmaceuticals make?
Lexicon Pharmaceuticals reported revenue of $38.54M for the twelve months to Sep 30, 2026, down 45.6% from a year earlier.
Does Lexicon Pharmaceuticals pay a dividend?
No. Lexicon Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Lexicon Pharmaceuticals report earnings next?
Lexicon Pharmaceuticals is expected to report Q4 FY2026 results on Mar 4, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has LXRX stock performed over the past year?
Including dividends, LXRX returned +24.3% over the past year, against +13.5% for the S&P 500.
Who are Lexicon Pharmaceuticals's competitors?
Companies most similar to Lexicon Pharmaceuticals by business, industry and size include VTVT, NAMS, TNXP, MCUJF, CPIX.
See a number that looks wrong?